跳至主要内容
临床试验/NCT05830994
NCT05830994招募中不适用

Randomized Sham-controlled Trial Investigating Efficacy of Gastric Peroral Endoscopic Myotomy in Treatment of Diabetic Gastroparesis

Hvidovre University Hospital2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年4月12日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
2
主要终点
Changes in gastric emptying

研究概览

简要总结

The goal of this randomized sham-controlled trial is to ivestigate efficacy and safety of G-POEM in treatment of diabetic gastroparesis and explore impact of G-POEM on glucose metabolism and incretine hormones.

详细描述

Study Design The study is a single-centre double-blinded sham-controlled randomized trial. All patients have the same baseline characterization. Patients and researchers will be blinded to allocation in trial. Before randomization patients will have an additional meal test performed addressing metabolic characterization of the incretine hormones at baseline. Patients will afterwards be allocated to either the group receiving G-POEM or to the control group where a sham procedure consisting of a gastroscopy with biopsy during general anaesthesia will be done. The randomization will be carried out per-operatively. A computer-generated bloc randomization with sizes of four will be applied. The study will consist of 5 study visits, with a follow-up of 90 days after procedure. Symptoms and adverse event will be monitored 7, 30, and 90 days after intervention. During the 90-day follow-up all primary and secondary outcome will be reassessed.

G-POEM procedure is carried out in general anaesthesia in the operating theatre at the Department of Surgery, Hvidovre Hospital. Procedures will be performed by experienced surgeons from the Gastro Unit at Hvidovre Hospital,who postoperatively will have no contact with the research team or study participants. Patients will receive the same care during hospitalization.

Patients allocated to sham procedure will have 4 mucosa biopsies from antrum. All biopsies will be handled with formalin and transported to Zealand University Hospital. Here they will be formalin fixed paraffin-embedded and kept in a biobank.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Patients and researchers will be blinded to allocation in the trial.

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The ability to give signed written informed consent,
  • Patients with diabetes and gastroparesis,
  • Age >18 years,
  • Gastroparesis is diagnosed with technetium-scintigraphy,
  • Normal gastroscopy,

排除标准

  • Ongoing cancer treatment or other concurrent illness that will make the patient unable to attend the study on the discretion of the investigator,
  • Recent gastrointestinal surgery,
  • Active duodenal/gastric ulcer disease,
  • Diseases in the ventricle or previously complicated upper abdominal surgery,
  • Previous bariatric surgery,
  • Pregnancy or breastfeeding,
  • Parkinson disease,
  • Persons who, in the judgement of the investigator, may be unable to follow the protocol, Use of metoclopramide, domperidone, prucalopride, ghrelin, macrolide antibiotics (eg, azithromycin, clarithromycin, erythromycin) during study period.
  • drugs with an anti-cholinergic mechanism,
  • Use of motility slowing agents: anticholinergic agents, calcium channel blockers, TCA, GLP-1 analogs, Lithium, diphenhydramin, glucagon, dopamine agonists, progesterone, L-dopa, calcitonine, octreotide, interferon alfa, sucralsulfate,
  • botulinum toxin injections (eg, Botox®) by pyloric injection less than 4 months prior to procedure

结局指标

主要结局

Changes in gastric emptying

时间窗: 90 days after intervention

assessed by technetium scintigraphy

次要结局

  • Concentration of C-peptide in pmol/L(90 days after intervention.)
  • Changes in continuous glucose(90 days after intervention.)
  • Incidence of Treatment-Emergent Adverse Events rated by the ASGE lexicon for adverse events(7,30 and 90 days)
  • Changes in postprandial incretinhormones(90 days after intervention.)
  • Changes in gastroparesis cardinal symptom index (GCSI)(7, 30 and 90 days after intervention.)
  • Changes in Plasma glucose(90 days after intervention.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Melina Svraka Hansen

Principal Investigator

Hvidovre University Hospital

研究点 (2)

Loading locations...

相似试验